Comparative Pharmacology
Head-to-head clinical analysis: BUTABARB versus BUTICAPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTABARB versus BUTICAPS.
BUTABARB vs BUTICAPS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Butalbital, a barbiturate, acts as a GABA-A receptor agonist, enhancing inhibitory neurotransmission in the CNS; acetaminophen inhibits cyclooxygenase (COX) activity and modulates endogenous cannabinoid receptors; caffeine is a non-selective adenosine receptor antagonist.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
500 mg orally every 8 hours.
None Documented
None Documented
Terminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Clinical Note
moderateButabarbital + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate."
Clinical Note
moderateButabarbital + Haloperidol
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol."
Clinical Note
moderateButabarbital + Clemastine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine."
Clinical Note
moderate3-5 hours (prolonged in renal impairment; dose adjustment required for CrCl <30 mL/min)
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
Renal (90% as unchanged drug), biliary/fecal (10%)
Category C
Category C
Barbiturate
Barbiturate
Butabarbital + Venlafaxine
"The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine."